Aevai Health Secures Investment from Round One to Revolutionize Biobank Data Collection

Eindhoven - In a major step to improve biobank operations throughout Europe and beyond, Aevai Health has received a new investment from student investment fund Round One Ventures. Biobanks collect biological samples and health information from participants for use in research. Aevai Health is at the forefront with its intelligent chatbot, Alva, to increase the efficiency in how biobanks collect participants’ data both remotely and onsite.

Round One Ventures has recognized the potential of Aevai Health's innovative approach by investing in the startup to launch its product into biobanks. The funding underscores strong confidence in Aevai Health's vision and future.”From the start we’ve seen the tremendous potential and drive the team has to revolutionize their industry," said Cas Verstappen, Managing Director of Round One. “We are very much looking forward to working intensively with the team over the coming months.”

With the new capital, Aevai Health plans to extend its reach to biobanks throughout the Netherlands and expand into other market opportunities. The investment will be essential in evolving Alva’s capabilities, ensuring it meets the complex demands of biobanks.

Fennie van der Graaf, CEO of Aevai Health, expressed excitement about the future, “This initial investment is a crucial step for us. It not only supports the success of our current pilot but also propels us towards acquiring our next major customer.” 

A closer look at Alva

Alva, Aevai Health’s intelligent chatbot, addresses challenges faced by biobanks, such as low survey completion rates, data collection gaps, and operational inefficiencies. By transforming medical surveys into interactive chatbot conversations, Alva improves data collection and enhances participant engagement, reducing the reliance on extensive staffing. Its continuous, personalized support and hybrid functionality, which combines user assistance with data collection using artificial intelligence, ensure that participants receive empathetic, context-driven interactions.

The biobank industry has seen a steady increase in the number of participants and biobanks, indicating a growing market and demand for reliable data collection methods. Aevai Health aims to set a new standard in this sector, offering a personalized, scalable solution that significantly enhances participant experience and operational efficiency.

About the team

Aevai Health was born from the collective vision of a dynamic team: CEO Fennie van der Graaf, CFO Alexandra Matei, CMO Naila Loudini, and CTO Giuseppe Marinelli. United by their diverse expertise and a shared passion, they are on a mission to improve data collection and boost participant engagement. Naila Loudini, a co-founder and CMO, emphasized the impact of their efforts, saying, “With Alva, we are doing more than improving data collection; we are giving participants a significant role in medical research. This approach not only improves the quality of research but also makes the process much more inclusive.'"

For more information, please contact our external relations manager at Daniela@roundone.ventures